

AUSTRALIAN COMMISSION ON SAFETY AND QUALITY IN HEALTH CARE



Medication Safety Standard 4

Part 4 – Medication management processes, partnering with patients and carers



Margaret Duguid, Pharmaceutical Advisor

Graham Bedford, Medication Safety Program Manager



Standard 4 Medicati on

Safety

The clinical workforce is supported for the prescribing, administering, storing, manufacturing, compounding and monitoring of medicines



4.9: Ensuring that current and accurate medicines information and decision support tools are readily available to clinical workforce

- What?
 - Implement and maintain up-to-date medicines information resources and decision support tools (manual or electronic) that are accessible to staff in clinical areas (at point of care) (4.9.1)
 - formulary information, prescribing requirements, approval systems
 - reference texts
 - policies, protocols and guidelines
 - drug interaction database
 - guidelines for safe administration of medicines (eg administering medicines via enteral tubes, intravenous injection)
 - antibiotic approval systems



4.9: Ensuring that current and accurate medicines information and decision support tools are readily available to clinical workforce


SHPA Australian Injectable Drugs Handbook SHPA Don't Rush to Crush Handbook








Hospital protocols, guidelines





Standard 4

Medicati on | Safety



- Clinical decision support for electronic medication management systems (EMMS)
- As a minimum the EMMS should reflect the **core** functional and technical features outlined in the Electronic Medication Management Systems A Guide to Safe Implementation Guide 2nd edition and be working towards the **desirable** features. Guide available from

http://www.safetyandquality.gov.au/our-work/medication-safety/electronic-medication-management-systems/




4.9: Ensuring that current and accurate medicines information and decision support tools are readily available to clinical workforce

- What?
 - Regular review of the use and content of clinical information and decision support tools, to ensure that resources are current, and are endorsed for use within the organisation (4.9.2)
 - Drug & Therapeutics Committee minutes/documentation
 - Risk assessment of drug information domain in MSSA
 - Q. These services are largely outsourced through the Clinical Information Access Portal (CIAP). We rely on the service provider to maintain up to date and relevant references. Is this sufficient?
 - A. Yes for CIAP. However the facility needs to review other resources used, hard and soft copy.

4.10: Ensuring that medicines are distributed and stored securely, safely (cont'd)

- What?
 - Regular review and risk assessment of medicines storage and distribution across the organisation.(4.10.1)
 - Do as part of overall self assessment
 - Audit against policies, procedures
 - Observation audits and "walk arounds"
 - Review medication incidents





4.10: Ensuring that medicines are distributed and stored securely, safely (Cont'd)

- What?
 - 4.10.2. Actions taken to reduce risks associated with storage and distribution of medicines
 - Policies and procedures
 - Safe handling and disposal of S8 medicines, cytotoxic products and hazardous substances
 - Purchasing for safety
 - Identifying risks and putting in place mitigation strategies
 - Safer distribution systems
 - Individual patient supply
 - Bedside lockers
 - Automated systems with patient profiling
 - Staff communication, alerts, bulletins



4.10: Ensuring that medicines are distributed and stored securely, safely

- What?
 - 4.10.2. Actions to reduce risks associated with storage and distribution (including confusion with look alike sound alike names)
 - Use of bar code scanners (dispensing, distribution)
 - Physical separation of products (e.g. look-alike, sound-alike products)
 - Use of Tall Man lettering (e-systems, infusion pump libraries, shelving, packaging)
 - National Tall Man lettering list

	4
fluVOXAMine	fluOXETine
lamIVUDine	lamOTRIGine
niMOdlpine	niFEdipine



4.10: Ensuring that medicines are distributed and stored securely, safely

- What?
- ► Temperature sensitive medicines are monitored and integrity of temperature-sensitive medicines maintained (4.10.3)
 - Temperatures measured, recorded, reviewed
- Q. We have installed electronic fridges that alarm when fridge is outside of set parameters. Do we have to document daily Min/Max temps for these fridges? Are we required to have documented evidence of daily checking?
- A. Need to have regular testing, scheduled maintenance of alarms. Temperature recording device in the fridge a record that the refrigerator is operating within the required temperature range. Monitor the record. This replaces the need to check and record the temperature daily.
- Health service needs to have policy for responding to the alarm.

4.10: Ensuring that medicines are distributed and stored securely, safely

- What?
 - Workforce disposes of unused, unwanted or expired medicines, in accordance with legislative and jurisdictional requirements (4.10.4)
 - S8 medicines audits
 - Disposal of cytotoxic products and hazardous substances (Work Health and Safetyissues)
 - Monitoring disposal of unused, unwanted or expired medicines (4.10.5)
 - Compliance with policy for disposal
 - Wastage



- 4.10. 5 System for disposal of unused, unwanted or expired medicines is regularly monitored
- Q. How are institutions auditing drug disposals? We can do S8 items but are other hospitals keeping a log of all items returned to their pharmacy departments.
- A. No. But hospitals need to do a risk assessment of the management of their pharmaceutical waste in terms of work health and safety, environmental safety and security of storage and disposal.




4.11: Identifying high risk medicines in the organisation and ensuring they are stored, prescribed, dispensed and administered safely


High risk medicines - APINCH (Antibiotics, Potassium, Insulin, Narcotics(S8s), Chemotherapy, Heparin (anticoagulants)


- What?
 - 4.11.1 Undertake an assessment of how high risk medicines are managed within the organisation
 - audits
 - incident analysis
 - risk assessment tools
 - drug usage evaluation programs
 - benchmarking activities.



4.11: Identifying high risk medicines in the organisation and ensuring they are stored, prescribed, dispensed and administered safely











MEDICATION ALERT!

From the Australian Council for Safety and Quality in Health Care

The purpose of this alert is to provide frontline health professionals and administrators with information on high risk medications that have the potential to cause serious or catastrophic harm to patients. The intention is to raise awareness of the potential harm and provide a strategy for local level response.

Alert 2, December 2005

Audits of compliance

VINCRISTINE can be fatal administered by the intrathecal route

For the attention of *Chief Executive Officers* and *Directors of Nursing*, *Pharmacy*, and *Medical Services*; *Doctors*, *Nurses* and *Pharmacists*For implementation immediately

Australian Cases

At least three cases of inadvertent intrathecal injection of vincristine have occurred in Australia over the last 20 years. Vincristine, a medicine commonly used in the treatment of leukaemias and lymphomas, is neurotoxic and must only be administered intravenously. Sentinel events associated with the inadvertent intrathecal administration of vincristine have been repeatedly reported in Australia and overseas. Adults and children are at risk with 50% of reported cases in each group. This error results in a fatal outcome in 85% of cases with devastating neurological effects in the few survivors.



MEDICATION ALERT!

From the Medication Safety Taskforce of the Australian Council for Safety and Quality in Health Care

The purpose of this alert is to provide frontline health professionals and administrators with information on high risk medications that have the potential to cause serious or catastrophic harm to patients. The intention is to raise awareness of the potential harm and provide a strategy for local level response.

Alert 1, October 2003

Intravenous **POTASSIUM CHLORIDE** can be fatal if given inappropriately

For the attention of Chief Executive Officers and Directors of Nursing, Pharmacy, and Medical Services; Doctors, Nurses and Pharmacists

For implementation immediately



4.11: Identifying high risk medicines in the organisation and ensuring they are stored, prescribed, dispensed and administered safely

- What?
 - Action taken to reduce risks of storing, prescribing, dispensing and administering high risk medicines (4.11.2)
 - List of high risk medicines available to staff, include in education
 - Policies, procedures and protocols
 - Guidelines for prescribing, dispensing, administering and monitoring specific high risk medicines such as anticoagulants, chemotherapy, opioids, insulin
 - Pre-loaded infusions potassium, heparin
 - Training on awareness of high risk meds
 - Implement safety alerts on high risk medicines
 - Monitor improvement activities
 - Warfarin NIMC audit
 - Potassium QUM indicator



- 4.11: Identifying high risk medicines in the organisation and ensuring they are stored, prescribed, dispensed and administered safely
- Q. What is a high risk medicine?
- A. Medicines that have a high risk of causing serious injury or death to a patient if they are misused or used in error. Errors not necessarily more common, effects more devastating.
 - APINCH
 - Use to develop own list
 - Institute of Safe Medication Practices list

www.safetyandquality.gov.au/our-work/medication-safety/medication-alerts/

Q. Can we prioritise actions to address risks with high risk medicines?

A. Yes

The clinical workforce informs patients about their options, risks and responsibilities for an agreed medication management plan.

Developmental



- 4.13: The clinical workforce informing patients and carers about medication treatment options, benefits and associated risks
- What?
 - Implement systems that support the provision of patient specific medicines information when medication treatment options are discussed (4.13.1)
 - Consumer Medicines Information provided (documented on MMP, in clinical notes)
 - Consumer information on specific medications, for example anticoagulants, chemotherapy
 - Patient specific medicines information accessible in clinical areas (4.13.2)
 - Hard copy or soft copy



4.14: Developing a medication management plan in partnership with patients and carers

- ► Why?
 - 30 50% medicines prescribed for long term conditions not used as prescribed ¹
 - Failure to achieve informed agreement or identify and provide support that patient needs to manage their medicines can lead to non-adherence ¹
 - The medication management (action) plan is intended to support health professionals and patients/carers in developing strategies to manage medicines safely and achieve treatment goals

 NICE. Medicines adherence – involving patients in decisions about prescribed medicines and supporting adherence Clinical Guideline CG 76 – January 2009



4.14: Developing a medication management plan in partnership with patients and carers

- What?
 - Undertake assessment of the patient's medication risks to identify medication management issues
 - Use Medication Risk Identification section on National Medication Management Plan
 - Develop a medication management (action) plan that establishes treatment goals and specifies actions required to achieve medication management goals (4.14.1).
 - List of medicines, allergies, administration aids
 - Goals of therapy, action to achieve goals
 - Communicate plan to patient and with the patient's consent to other relevant health care professionals


- 4.14 Developing a medication management plan in partnership with patients, carers
- Q. What is a medication management plan? Is it the National Medication Management Plan?
- A. No. It is the consumer medication action plan referred to in APAC Guiding principles to achieve continuity of medication management.
 - Plan for patient's medication management
 - Treatment goals and actions, medicines list, changes
 - Provided to patient, carer
 - Commission developing a template late 2013



4.15: Providing current medicines information to patients in a format that meets their needs whenever new medicines are prescribed or dispensed

- What?
 - Identify medicines information resources that are in a format that can be used and understood by patients and carers when new medicines are prescribed/supplied or medicines changed(4.15.1)
 - Similar evidence to 4.14
 - Interpreter services available for CALD patients
 - Written information in patients own language e.g. multilingual medicines lists
 - NPS MedicineWise resources
 - Improve medicines information provided in response to patient feedback (4.15.2)
 - Action taken in response to complaints, patient surveys





Do not take this medicine if you have or have had any of the

Acute breathing difficulties such as bronchitis unstable asthma or

Panamax may be used during pregrancy and if you are breastfeeding. However, it is recommended that non drug therapy such as rest and massage be tried

Do not use Panamax after the expiry date (EXP) printed on the nack or bottle

may have no effect at all, or worse, have an entirely unexpected effect.

Do not use Panamay if the packaging is torn or shows signs of

any other complaint unless your doctor says it is safe. Do not give this medicine to anyone for which it is not intended.

Before you start to take it

When you must not use it

You should not take Panamax if you are allergic to paracetamol or any of the ingredients listed under "Product Description".

Before you use

Panamax

The symptoms of an allergic reaction may include a rash, asthma attack or havfever.

following medical conditions:

emphysema.

If you take it after the expiry date it

Do not use this medicine to treat

You must tell your doctor if:

- * You have allergies to any ingredients listed under "Product Description" at the end of this
- You have liver or kidney problems
- You drink large quantities of alcohol

You should tell your doctor if you are taking any other medicines.

Including any of the following:

- Any medicines which thin the blood, for example warfarin
- Medicines to treat epilepsy Metoclopramide, a medicine used to control nausea and vomiting
- Propantheline, a drug used to treat stomach ulcers
- Chloramphenicol, an antibiotic used to treat ear and eve
- infections
- Zidovudine and rifampicin, drugs used to treat infections

These medicines may be affected by Panamax or may affect how well Panamax works

Your doctor or pharmacist can tell you what to do if you are taking any of these medicines

If you have not told your doctor about any of these things, tell him/her before you take Panamax.



Australian Commission on Safety and Quality in Health Care

Medication Safety Program

www.safetyandquality.gov.au

Email: mail@safetyandquality.gov.au

margaret.duguid@safetyandquality.gov.au

